Delving into the Latest Updates on Melilotus Extract with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

草木犀流浸液片, SETUS-M, TAKAVENSU

+ [2]

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesDigestive System DisordersOther Diseases

Active Indication

TumescenceHemorrhoids

Inactive Indication-

Originator Organization

Seiko Eiyo Yakuhin Co., Ltd.

Active Organization

Takata Seiyaku Co., Ltd.

Seiko Eiyo Yakuhin Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (24 Jul 2006),

Hemorrhoids

Regulation-

Login to view timeline

本试验旨在研究单次空腹口服湖南明瑞制药有限公司研制、生产的草木犀流浸液片〔400 mg（含草木犀流浸液25 mg）〕的药代动力学特征；以生晃荣养药品株式会社生产的草木犀流浸液片〔消脱止-M®，400 mg（含草木犀流浸液25 mg）〕为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞。

[Translation]

The purpose of this study was to study the pharmacokinetic characteristics of a single oral fasting dose of Mesorhizium oxyphylla fluid infusion tablets (400 mg (containing Mesorhizium oxyphylla fluid infusion 25 mg)) developed and produced by Hunan Mingrui Pharmaceutical Co., Ltd.; using Mesorhizium oxyphylla fluid infusion tablets (Xiaoduozhi-M®, 400 mg (containing Mesorhizium oxyphylla fluid infusion 25 mg)) produced by Shenghuang Rongyang Pharmaceutical Co., Ltd. as the reference preparation, and to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations.

Start Date02 Apr 2021

Sponsor / Collaborator